Eckart Schott
Works:
- Daclatasvir : erster NS5A-Inhibitor für die orale, interferonfreie Therapie der chronischen Hepatitis C
- Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study
- Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection
- Outcomes and costs of treating hepatitis C patients in the era of first generation protease inhibitors – results from the PAN study